

Special Issue

The 10th Anniversary of *Vaccines*—Innate and Adaptive Immunity in Vaccination

Message from the Guest Editor

In 2022, we will celebrate the 10th volume of the journal *Vaccines* (ISSN 2076-393X), and it is our pleasure to invite you to join us on this wonderful occasion. To mark this significant milestone, we are launching the Special Issue entitled “The 10th Anniversary of Vaccines—Innate and Adaptive Immunity in Vaccination”. This Special Issue will include high-quality papers on topics within the scope of the section “Innate and Adaptive Immunity in Vaccination” of *Vaccines*. In this Special Issue, original research articles and reviews are welcome. The research areas may include, but are not limited to, the following:

- Innate immune recognition, activation of inflammasome and cytokine responses to vaccines;
- Route of vaccination and how it may impact vaccine responses;
- Vaccine delivery systems;
- Novel vaccine strategies;
- Pathogen immune evasion strategies that overcome vaccine responses;
- Trained immunity-based vaccines.

We look forward to receiving your contributions.

Guest Editor

Prof. Dr. Betsy C. Herold

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/116341

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).